BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » HSCs » Page 3

Hematopoietic Stem Cells (HSCs)

Hematopoietic Stem Cells: What Diseases Can these Stem Cells Treat?

By

Hematopoietic stem cells (HSCs) are defined as stem cells that have a preference for becoming cells of the blood and immune system, such as white blood cells, red blood cells, and platelets. Found in the peripheral blood and bone marrow, hematopoietic stem cells are also present in plentiful supply within the umbilical cord blood of newborn babies.

For the past thirty years, cord blood has been used within transplant medicine, including for the treatment of leukemia and other blood diseases. For most conditions in which a bone marrow or peripheral blood stem cell transplant is an option, a cord blood transplant is a potential alternative.

Hematopoietic Stem Cells

In this article:

[Read more…]

When Did Cord Blood Banking Start? Landmark Events in Cord Blood & Tissue

By

The global cord blood industry came into existence in the early 1990’s with the formation of several leading cord blood banks in the USA, followed by the establishment of cord blood banks across the globe. However, the history of cord blood stem cell transplantation begins much earlier than that.

The History of Banking Cord Blood

In this article:

[Read more…]

Could NiCord® by Gamida Cell Introduce a Paradigm Shift to HSCT?

By

Gamida CellGamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company is developing a diverse clinical pipeline based on its proprietary NAM technology platform. It lead program, NiCord®, is now in Phase 3 development for allogeneic bone marrow transplantation.

NiCord® was granted Breakthrough Therapy Designation by the FDA, as well orphan drug designation by the European Medicines Agency (EMA). [Read more…]

Cord Blood Industry Trends – Clinical Trials, Publications, Patents, Grants, & More

By

With the global cord blood banking industry maturing and consolidating over the past five years, it is more important than ever to be well-educated about cord blood industry trends. There are now fewer market players, because numerous small cord blood banks have either been acquired or gone out of business.

However, this era of maturation and consolidation has had as many benefits to surviving cord blood banks as drawbacks. On average, the remaining market participants are now larger, stronger, better capitalized, and storing larger quantities of cord blood and tissue units than when the market was more fragmented.

[Read more…]

BioInformant's World-Class Clients